AngioDynamics (ANGO)
(Delayed Data from NSDQ)
$6.37 USD
-1.28 (-16.73%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $6.58 +0.21 (3.30%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.37 USD
-1.28 (-16.73%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $6.58 +0.21 (3.30%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
Zacks News
Here's Why You Should Add AngioDynamics Stock to Your Portfolio
by Zacks Equity Research
ANGO shows growth potential with its NanoKnife system and expanding U.S. sales but faces challenges from pricing pressure and macroeconomic factors.
AngioDynamics (ANGO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of 26.67% and 1.46%, respectively, for the quarter ended August 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's What Could Help AngioDynamics (ANGO) Maintain Its Recent Price Strength
by Zacks Equity Research
AngioDynamics (ANGO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
New Strong Buy Stocks for September 30th
by Zacks Equity Research
MRX, ANGO, OPRA, ATAT and PAM have been added to the Zacks Rank #1 (Strong Buy) List on September 30, 2024.
ANGO Initiates RECOVER-AV Trial for AlphaVac F1885 in Europe
by Zacks Equity Research
AngioDynamics' RECOVER-AV trial evaluates the AlphaVac F1885 System's safety and efficacy in treating acute pulmonary embolism in Europe.
New Strong Buy Stocks for September 13th
by Zacks Equity Research
ARCT, MHO, FMBH, PAM and ANGO have been added to the Zacks Rank #1 (Strong Buy) List on September 13, 2024.
New Strong Buy Stocks for September 9th
by Zacks Equity Research
DEC, AFRM, CRNC, ANGO and GIII have been added to the Zacks Rank #1 (Strong Buy) List on September 9, 2024.
AngioDynamics Stock Falls Despite CE Mark for Auryon System
by Zacks Equity Research
ANGO's Auryon Atherectomy System earns CE Mark, which expands its European market reach and enhances PAD treatment with advanced laser technology.
AngioDynamics (ANGO) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
AngioDynamics (ANGO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AngioDynamics (ANGO) Down 3.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Accuray's (ARAY) Radixact for Cancer Treatment Debuts in US
by Zacks Equity Research
Accuray's (ARAY) Radixact System with VitalHold technology is set to enhance precision and comfort in radiation therapy.
Does AngioDynamics (ANGO) Have the Potential to Rally 77.03% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for AngioDynamics (ANGO) points to a 77% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Should You Buy AngioDynamics (ANGO) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Boston Scientific (BSX) Rides on Global Growth, Buyouts
by Zacks Equity Research
Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.
Wall Street Analysts Predict a 74.25% Upside in AngioDynamics (ANGO): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 74.3% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
New Strong Buy Stocks for July 29th
by Zacks Equity Research
KRO, FUNC, PRG, ANGO and HGTY have been added to the Zacks Rank #1 (Strong Buy) List on July 29, 2024.
AngioDynamics (ANGO) Q4 Earnings Top Estimates, Gross Margin Down
by Zacks Equity Research
AngioDynamics (ANGO) registers overall strong top-line results on a pro-forma basis in fourth-quarter fiscal 2024, driven by strength in the Med Tech business.
AngioDynamics (ANGO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of 70% and 0.18%, respectively, for the quarter ended May 2024. Do the numbers hold clues to what lies ahead for the stock?
AngioDynamics' (ANGO) AlphaVac System Gets CE Mark Approval
by Zacks Equity Research
AngioDynamics (ANGO) announces the European CE Mark approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.
AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Despite strength in the Med Tech business, AngioDynamics (ANGO) registers overall soft performance in third-quarter fiscal 2024.
AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment
by Zacks Equity Research
AngioDynamics (ANGO) announces the FDA's approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.
AngioDynamics (ANGO) Settles Patent Litigations With BD
by Zacks Equity Research
AngioDynamics (ANGO) announces its settlement agreement with BD's affiliate, C.R. Bard, to resolve a 10-year dispute over outstanding patent litigation.
Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AngioDynamics (ANGO) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
In the most recent trading session, AngioDynamics (ANGO) closed at $5.37, indicating a -0.74% shift from the previous trading day.
Why AngioDynamics (ANGO) Dipped More Than Broader Market Today
by Zacks Equity Research
In the most recent trading session, AngioDynamics (ANGO) closed at $5.67, indicating a -1.39% shift from the previous trading day.